Paige, an artificial intelligence (AI) technology company, has expanded the Paige PanCancer Detect application to detect common, rare variants, and precursor lesions of cancer.
This AI tool can now identify cancer in over 40 tissue and organ types.
Launched in 2024, it was initially built to help pathologists detect cancer in 17 different tissues.
The upgrade uses Virchow V2, Paige’s advanced foundation model built in partnership with Microsoft. Virchow V2 is trained on three million digitised slides and 1.8 billion parameters.
Paige PanCancer Detect can streamline pathology labs by automatically screening cases. It prioritises cancer cases, helping pathologists focus on critical diagnoses and reducing the time to diagnosis.
The AI tool also enhances quality control by quickly screening all cases, identifying potential diagnostic discrepancies, and reducing errors. This helps alleviate resource constraints in labs and ultimately improves patient care.
Additionally, the AI technology company launched the OmniScreen module in August 2024 for the evaluation of over 505 genes and the detection of 1,228 molecular biomarkers from routine haematoxylin and eosin (H&E)-stained digital pathology slides.
Paige AI science director Siqi Liu said: “By leveraging the tissue-agnostic capabilities of Virchow V2, Paige PanCancer Detect transforms cancer detection into a broad, scalable AI solution that generalises the concept of ‘cancer’ across tissues.
“This unique approach, originally demonstrated in our research published in Nature Medicine, has shown in our studies to be effective in detecting both rare cancer variants, low-prevalence cancers, and even precancerous lesions, challenges that traditional task-specific AI models often struggle to address.”
The first version of Paige PanCancer Detect has been used and independently tested in a study with 62 challenging cases across 16 tissue types.
In the trial, the software flagged one case with a discrepant result, which was later confirmed in favour of the AI’s assessment.
Paige PanCancer Detect is available through Paige’s FullFocus image viewer. It will soon be accessible via established platform partners, including PathPresenter, Aiforia, Indica Labs, PathAI, and Gestalt.
Last month, an AI technology company secured the US Food and Drug Administration (FDA) 510(k) clearance for the use of its FullFocus digital pathology image viewer with Leica Aperio GT 450 DX and Hamamatsu NanoZoomer S360MD.
In September 2021, Paige became the first company to receive FDA marketing approval for its AI-enabled digital pathology diagnostic, Paige Prostate.
